Clinical Trial

A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-09; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2026-02-20
Trial Details
NCT Number NCT07215975
Lead Sponsor Bristol-Myers Squibb
Conditions β-thalassemia
Enrollment 200 participants
Start Date 2026-06-25
Primary Completion 2030-02-28 (estimated)
Study Completion 2031-04-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-02